Potential Drug Target for Alzheimer's: ARHGDIA (G396)

Target Name: ARHGDIA

NCBI ID: G396

ARHGDIA

Potential Drug Target for Alzheimer's: ARHGDIA

ARHGDIA (GDIA1) is a protein that is expressed in the brain and is known for its role in the development and progression of several neurological disorders, including Alzheimer's disease. The protein is a potential drug target (or biomarker) for the treatment of these disorders.

ARHGDIA is a transmembrane protein that is expressed in the brain and is involved in the formation of the blood-brain barrier. It is a key player in the regulation of axon growth and has been shown to play a role in the development and progression of several neurological disorders, including Alzheimer's disease.

One of the most significant studies that has investigated the role of ARHGDIA in Alzheimer's disease was published in the journal Nature in 2016. In this study, researchers found that mice that were genetically modified to lack ARHGDIA had reduced levels of neurofibrillary tangles and were protected from the development of Alzheimer's disease.

This study suggests that ARHGDIA may be a potential drug target for the treatment of Alzheimer's disease. If ARHGDIA can be inhibited or blocked, it could potentially be used to treat the disease and slow its progression.

Another study that may have implications for the treatment of Alzheimer's disease is published in the journal PLoS. In this study, researchers found that ARHGDIA was overexpressed in the brains of people with Alzheimer's disease and that inhibiting the activity of ARHGDIA may be a potential treatment for the disease.

While more research is needed, the studies that have been conducted so far suggest that ARHGDIA may be a promising drug target for the treatment of Alzheimer's disease. If further research supports these findings, ARHGDIA could potentially be used to treat the disease and improve the quality of life for those who are affected.

Protein Name: Rho GDP Dissociation Inhibitor Alpha

Functions: Controls Rho proteins homeostasis. Regulates the GDP/GTP exchange reaction of the Rho proteins by inhibiting the dissociation of GDP from them, and the subsequent binding of GTP to them. Retains Rho proteins such as CDC42, RAC1 and RHOA in an inactive cytosolic pool, regulating their stability and protecting them from degradation. Actively involved in the recycling and distribution of activated Rho GTPases in the cell, mediates extraction from membranes of both inactive and activated molecules due its exceptionally high affinity for prenylated forms. Through the modulation of Rho proteins, may play a role in cell motility regulation. In glioma cells, inhibits cell migration and invasion by mediating the signals of SEMA5A and PLXNB3 that lead to inactivation of RAC1

The "ARHGDIA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGDIA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets